Authors: Popov, I Jelic, S Radosavljevic, D Nikolic-Tomasevic, Z

Citation: I. Popov et al., Amsacrine and cisplatin in poor prognosis patients with metastatic transitional cell carcinoma of the urothelium: A phase-II study, EUR UROL, 40(3), 2001, pp. 324-329

Authors: Nikolic-Tomasevic, Z Jelic, S Popov, I Radosavljevic, D Mitrovic, L

Citation: Z. Nikolic-tomasevic et al., Tumor 'flare' hypercalcemia - An additional indication for bisphosphonates?, ONCOL-BASEL, 60(2), 2001, pp. 123-126

Authors: Nikolic-Tomasevic, Z Jelic, S Popov, I Radosavljevic, D

Citation: Z. Nikolic-tomasevic et al., Irinotecan as second-line treatment in metastatic colorectal cancer: Dilemmas regarding patient selection and toxicity prediction, J CHEMOTHER, 12(3), 2000, pp. 244-251

Authors: Popov, I Jelic, S Radulovic, S Radosavljevic, D Nikolic-Tomasevic, Z

Citation: I. Popov et al., Eight-hour infusion versus bolus injection of doxorubicin in the EAP regimen in patients with advanced gastric cancer: A prospective randomised trial, ANN ONCOL, 11(3), 2000, pp. 343-348

Authors: Popov, I Jelic, S Radosavljevic, D Nikolic-Tomasevic, Z

Citation: I. Popov et al., The role of stable disease in objective response assessment and its impacton survival in advance colorectal cancer: Is "stable disease" a homogenousresponse category?, NEOPLASMA, 46(2), 1999, pp. 132-139